1. Chang Y, Cesarman E, Pessin MS, et al: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-1869.
2. Cesarman E, Chang Y, Moore PS, et al: Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332: 1186-1191.
3. Soulier J, Grollet L, Oksenhendler E, et al: Kaposi's sarcoma-associated herpesviruslike DNA sequences in multicentric Castleman's disease. Blood 1995; 86: 1276-1280.
4. Uldrick TS, Wang V, O'Mahony D, et al: An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis 2010; 51: 350-358.
5. Polizzotto MN, Uldrick TS, Wyvill KM, et al: Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS). Clin Infect Dis 2016; 62: 730-738.
6. Cattani P, Cerimele F, Porta D, et al: Age-specific seroprevalence of Human Herpesvirus 8 in Mediterranean regions. Clin Microbiol Infect 2003; 9: 274-279.
7. Etta EM, Alayande DP, Mavhandu-Ramarumo LG, et al: HHV-8 Seroprevalence and 52 Genotype Distribution in Africa, 1998(-)2017: A Systematic Review. Viruses 2018; 10.
8. Minhas V, Wood C: Epidemiology and transmission of Kaposi's sarcoma-associated herpesvirus. Viruses 2014; 6: 4178-4194.
9. Katano H, Iwasaki T, Baba N, et al: Identification of antigenic proteins encoded by human herpesvirus 8 and seroprevalence in the general population and among patients with and without Kaposi's sarcoma. J Virol 2000; 74: 3478-3485.
10. Katano H, Yokomaku Y, Fukumoto H, et al: Seroprevalence of Kaposi's sarcomaassociated herpesvirus among men who have sex with men in Japan. J Med Virol 2013; 85: 1046-1052.
11. Martin JN, Ganem DE, Osmond DH, et al: Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998; 338: 948-954.
12. Melbye M, Cook PM, Hjalgrim H, et al: Risk factors for Kaposi's-sarcoma-associated herpesvirus (KSHV/HHV-8) seropositivity in a cohort of homosexual men, 1981-1996. Int J Cancer 1998; 77: 543-548.
13. Eltom MA, Mbulaiteye SM, Dada AJ, et al: Transmission of human herpesvirus 8 by sexual activity among adults in Lagos, Nigeria. AIDS 2002; 16: 2473-2478.
14. Lavreys L, Chohan B, Ashley R, et al: Human herpesvirus 8: seroprevalence and correlates in prostitutes in Mombasa, Kenya. J Infect Dis 2003; 187: 359-363.
15. Malope BI, MacPhail P, Mbisa G, et al: No evidence of sexual transmission of Kaposi's 53 sarcoma herpes virus in a heterosexual South African population. AIDS 2008; 22: 519526.
16. Boldogh I, Szaniszlo P, Bresnahan WA, et al: Kaposi's sarcoma herpesvirus-like DNA sequences in the saliva of individuals infected with human immunodeficiency virus. Clin Infect Dis 1996; 23: 406-407.
17. Smith NA, Sabin CA, Gopal R, et al: Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. J Infect Dis 1999; 180: 600-606.
18. Andreoni M, Sarmati L, Nicastri E, et al: Primary human herpesvirus 8 infection in immunocompetent children. JAMA 2002; 287: 1295-1300.
19. Kanno T, Sato Y, Nakamura T, et al: Genotypic and clinicopathological characterization of Kaposi's sarcoma-associated herpesvirus infection in Japan. J Med Virol 2010; 82: 400-406.
20. Dollery SJ: Towards Understanding KSHV Fusion and Entry. Viruses 2019; 11.
21. Russo JJ, Bohenzky RA, Chien MC, et al: Nucleotide sequence of the Kaposi sarcomaassociated herpesvirus (HHV8). Proc Natl Acad Sci U S A 1996; 93: 14862-14867.
22. Sun R, Lin SF, Gradoville L, et al: Polyadenylylated nuclear RNA encoded by Kaposi sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A 1996; 93: 11883-11888.
23. Cai X, Lu S, Zhang Z, et al: Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc Natl Acad Sci U S A 2005; 102: 54 5570-5575.
24. Samols MA, Hu J, Skalsky RL, et al: Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus. J Virol 2005; 79: 9301-9305.
25. Cesarman E, Nador RG, Bai F, et al: Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma. J Virol 1996; 70: 8218-8223.
26. Sarid R, Sato T, Bohenzky RA, et al: Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med 1997; 3: 293-298.
27. Dupin N, Fisher C, Kellam P, et al: Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 1999; 96: 4546-4551.
28. Ye F, Lei X, Gao SJ: Mechanisms of Kaposi's Sarcoma-Associated Herpesvirus Latency and Reactivation. Adv Virol 2011; 2011: 193860.
29. Purushothaman P, Dabral P, Gupta N, et al: KSHV Genome Replication and Maintenance. Front Microbiol 2016; 7: 54.
30. Yan L, Majerciak V, Zheng ZM, et al: Towards Better Understanding of KSHV Life Cycle: from Transcription and Posttranscriptional Regulations to Pathogenesis. Virol Sin 2019; 34: 135-161. 55
31. Ballestas ME, Chatis PA, Kaye KM: Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 1999; 284: 641-644.
32. Gradoville L, Gerlach J, Grogan E, et al: Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line. J Virol 2000; 74: 6207-6212.
33. Davis DA, Rinderknecht AS, Zoeteweij JP, et al: Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood 2001; 97: 3244-3250.
34. Ye F, Zhou F, Bedolla RG, et al: Reactive oxygen species hydrogen peroxide mediates Kaposi's sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog 2011; 7: e1002054.
35. Renne R, Zhong W, Herndier B, et al: Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med 1996; 2: 342-346.
36. Miller G, Heston L, Grogan E, et al: Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J Virol 1997; 71: 314-324.
37. Sun R, Lin SF, Gradoville L, et al: A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A 1998; 95: 1086610871.
38. Lukac DM, Kirshner JR, Ganem D: Transcriptional activation by the product of open 56 reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells. J Virol 1999; 73: 9348-9361.
39. Said J, Cesarman E: Primary effusion lymphoma. eds Swerdlow SH, Campo E, Harris NL, et al, In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed, International Agency for Research on Cancer (IARC), Lyon, 2017; 323324.
40. Nador RG, Cesarman E, Chadburn A, et al: Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996; 88: 645-656.
41. Said W, Chien K, Takeuchi S, et al: Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells. Blood 1996; 87: 4937-4943.
42. Beral V, Peterman T, Berkelman R, et al: AIDS-associated non-Hodgkin lymphoma. Lancet 1991; 337: 805-809.
43. Goedert JJ: The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol 2000; 27: 390-401.
44. Engels EA, Pfeiffer RM, Goedert JJ, et al: Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645-1654.
45. Ota Y, Hishima T, Mochizuki M, et al: Classification of AIDS-related lymphoma cases 57 between 1987 and 2012 in Japan based on the WHO classification of lymphomas, fourth edition. Cancer Med 2014; 3: 143-153.
46. Friborg J, Jr., Kong W, Hottiger MO, et al: p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999; 402: 889-894.
47. Radkov SA, Kellam P, Boshoff C: The latent nuclear antigen of Kaposi sarcomaassociated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000; 6: 1121-1127.
48. Fujimuro M, Wu FY, ApRhys C, et al: A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med 2003; 9: 300306.
49. Bubman D, Guasparri I, Cesarman E: Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene 2007; 26: 4979-4986.
50. Liu J, Martin HJ, Liao G, et al: The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. J Virol 2007; 81: 10451-10459.
51. Di Bartolo DL, Cannon M, Liu YF, et al: KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood 2008; 111: 47314740.
52. Santag S, Jager W, Karsten CB, et al: Recruitment of the tumour suppressor protein p73 58 by Kaposi's Sarcoma Herpesvirus latent nuclear antigen contributes to the survival of primary effusion lymphoma cells. Oncogene 2013; 32: 3676-3685.
53. Gao SJ, Boshoff C, Jayachandra S, et al: KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene 1997; 15: 1979-1985.
54. Hideshima T, Chauhan D, Teoh G, et al: Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. Clin Cancer Res 2000; 6: 1180-1189.
55. Seo T, Park J, Lee D, et al: Viral interferon regulatory factor 1 of Kaposi's sarcomaassociated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis. J Virol 2001; 75: 6193-6198.
56. Seo T, Park J, Choe J: Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 1 inhibits transforming growth factor-beta signaling. Cancer Res 2005; 65: 17381747.
57. Wu J, Xu Y, Mo D, et al: Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6 promotes cell proliferation and migration by upregulating DNMT1 via STAT3 activation. PLoS One 2014; 9: e93478.
58. Ansari MQ, Dawson DB, Nador R, et al: Primary body cavity-based AIDS-related lymphomas. Am J Clin Pathol 1996; 105: 221-229.
59. Arvanitakis L, Mesri EA, Nador RG, et al: Establishment and characterization of a 59 primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 1996; 88: 2648-2654.
60. Horenstein MG, Nador RG, Chadburn A, et al: Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. Blood 1997; 90: 1186-1191.
61. Simonelli C, Spina M, Cinelli R, et al: Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003; 21: 3948-3954.
62. Boulanger E, Gerard L, Gabarre J, et al: Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005; 23: 4372-4380.
63. Zhou FC, Zhang YJ, Deng JH, et al: Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J Virol 2002; 76: 6185-6196.
64. Boshoff C, Gao SJ, Healy LE, et al: Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood 1998; 91: 1671-1679.
65. Carbone A, Cilia AM, Gloghini A, et al: Establishment and characterization of EBV60 positive and EBV-negative primary effusion lymphoma cell lines harbouring human herpesvirus type-8. Br J Haematol 1998; 102: 1081-1089.
66. Jones D, Ballestas ME, Kaye KM, et al: Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient. N Engl J Med 1998; 339: 444-449.
67. Katano H, Hoshino Y, Morishita Y, et al: Establishing and characterizing a CD30positive cell line harboring HHV-8 from a primary effusion lymphoma. J Med Virol 1999; 58: 394-401.
68. Carbone A, Cilia AM, Gloghini A, et al: Characterization of a novel HHV-8-positive cell line reveals implications for the pathogenesis and cell cycle control of primary effusion lymphoma. Leukemia 2000; 14: 1301-1309.
69. Goto H, Kojima Y, Nagai H, et al: Establishment of a CD4-positive cell line from an AIDS-related primary effusion lymphoma. Int J Hematol 2013; 97: 624-633.
70. Osawa M, Mine S, Ota S, et al: Establishing and characterizing a new primary effusion lymphoma cell line harboring Kaposi's sarcoma-associated herpesvirus. Infect Agent Cancer 2016; 11: 37.
71. Marks PA: The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010; 19: 1049-1066.
72. Chueh AC, Tse JW, Togel L, et al: Mechanisms of Histone Deacetylase InhibitorRegulated Gene Expression in Cancer Cells. Antioxid Redox Signal 2015; 23: 66-84. 61
73. Sarkar S, Abujamra AL, Loew JE, et al: Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Res 2011; 31: 2723-2732.
74. Wang X, Waschke BC, Woolaver RA, et al: Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas. Cancer Immunol Res 2019; 7: 1318-1331.
75. Zhang XD, Gillespie SK, Borrow JM, et al: The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 2004; 3: 425435.
76. Chen S, Dai Y, Pei XY, et al: Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol 2009; 29: 6149-6169.
77. You BR, Park WH: Suberoyl bishydroxamic acid inhibits the growth of A549 lung cancer cells via caspase-dependent apoptosis. Mol Cell Biochem 2010; 344: 203-210.
78. Yang X, Zhang N, Shi Z, et al: Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells. Mol Med Rep 2015; 11: 2908-2912.
79. Greenblatt DY, Cayo M, Ning L, et al: Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells. J Gastrointest Surg 62 2007; 11: 1515-1520; discussion 1520.
80. Adler JT, Hottinger DG, Kunnimalaiyaan M, et al: Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery 2008; 144: 956-961; discussion 961-952.
81. Ning L, Greenblatt DY, Kunnimalaiyaan M, et al: Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells. Oncologist 2008; 13: 98-104.
82. Xiao X, Ning L, Chen H: Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors. Mol Cancer Ther 2009; 8: 350-356.
83. Li J, Zheng X, Gao M, et al: Suberoyl bis-hydroxamic acid activates Notch1 signaling and induces apoptosis in anaplastic thyroid carcinoma through p53. Oncol Rep 2017; 37: 458-464.
84. Vieira J, O'Hearn PM: Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expression. Virology 2004; 325: 225-240.
85. Kati S, Hage E, Mynarek M, et al: Generation of high-titre virus stocks using BrK.219, a B-cell line infected stably with recombinant Kaposi's sarcoma-associated herpesvirus. J Virol Methods 2015; 217: 79-86.
86. Fakhari FD, Dittmer DP: Charting latency transcripts in Kaposi's sarcoma-associated 63 herpesvirus by whole-genome real-time quantitative PCR. J Virol 2002; 76: 6213-6223.
87. Yanagisawa Y, Sato Y, Asahi-Ozaki Y, et al: Effusion and solid lymphomas have distinctive gene and protein expression profiles in an animal model of primary effusion lymphoma. J Pathol 2006; 209: 464-473.
88. Kanno T, Uehara T, Osawa M, et al: Fumagillin, a potent angiogenesis inhibitor, induces Kaposi sarcoma-associated herpesvirus replication in primary effusion lymphoma cells. Biochem Biophys Res Commun 2015; 463: 1267-1272.
89. Okuno T, Jiang YB, Ueda K, et al: Activation of human herpesvirus 8 open reading frame K5 independent of ORF50 expression. Virus Res 2002; 90: 77-89.
90. Katano H, Sato Y, Kurata T, et al: High expression of HHV-8-encoded ORF73 protein in spindle-shaped cells of Kaposi's sarcoma. Am J Pathol 1999; 155: 47-52.
91. Katano H, Sato Y, Kurata T, et al: Expression and localization of human herpesvirus 8encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 2000; 269: 335-344.
92. de Hoon MJ, Imoto S, Nolan J, et al: Open source clustering software. Bioinformatics 2004; 20: 1453-1454.
93. Saldanha AJ: Java Treeview--extensible visualization of microarray data. Bioinformatics 2004; 20: 3246-3248.
94. Robinson JT, Thorvaldsdottir H, Winckler W, et al: Integrative genomics viewer. Nat 64 Biotechnol 2011; 29: 24-26.
95. Thorvaldsdottir H, Robinson JT, Mesirov JP: Integrative Genomics Viewer (IGV): highperformance genomics data visualization and exploration. Brief Bioinform 2013; 14: 178-192.
96. Robinson JT, Thorvaldsdottir H, Wenger AM, et al: Variant Review with the Integrative Genomics Viewer. Cancer Res 2017; 77: e31-e34.
97. Lu F, Zhou J, Wiedmer A, et al: Chromatin remodeling of the Kaposi's sarcomaassociated herpesvirus ORF50 promoter correlates with reactivation from latency. J Virol 2003; 77: 11425-11435.
98. Chen J, Ye F, Xie J, et al: Genome-wide identification of binding sites for Kaposi's sarcoma-associated herpesvirus lytic switch protein, RTA. Virology 2009; 386: 290-302.
99. Gunther T, Grundhoff A: The epigenetic landscape of latent Kaposi sarcoma-associated herpesvirus genomes. PLoS Pathog 2010; 6: e1000935.
100. Dignam JD, Martin PL, Shastry BS, et al: Eukaryotic gene transcription with purified components. Methods Enzymol 1983; 101: 582-598.
101. Shaw RN, Arbiser JL, Offermann MK: Valproic acid induces human herpesvirus 8 lytic gene expression in BCBL-1 cells. AIDS 2000; 14: 899-902.
102. Chen J, Ueda K, Sakakibara S, et al: Activation of latent Kaposi's sarcoma-associated herpesvirus by demethylation of the promoter of the lytic transactivator. Proc Natl Acad 65 Sci U S A 2001; 98: 4119-4124.
103. Toth Z, Maglinte DT, Lee SH, et al: Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog 2010; 6: e1001013.
104. Jacobs SR, Damania B: The viral interferon regulatory factors of KSHV: immunosuppressors or oncogenes? Front Immunol 2011; 2: 19.
105. Munoz-Fontela C, Marcos-Villar L, Gallego P, et al: Latent protein LANA2 from Kaposi's sarcoma-associated herpesvirus interacts with 14-3-3 proteins and inhibits FOXO3a transcription factor. J Virol 2007; 81: 1511-1516.
106. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
107. Gu W, Roeder RG: Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90: 595-606.
108. Shieh SY, Ikeda M, Taya Y, et al: DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91: 325-334.
109. Chen C, Edelstein LC, Gelinas C: The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000; 20: 2687-2695.
110. Keller SA, Schattner EJ, Cesarman E: Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000; 96: 2537-2542.
111. Keller SA, Hernandez-Hopkins D, Vider J, et al: NF-kappaB is essential for the 66 progression of KSHV- and EBV-infected lymphomas in vivo. Blood 2006; 107: 32953302.
112. Autin P, Blanquart C, Fradin D: Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors. Cancers (Basel) 2019; 11.
113. Bray SJ: Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 2006; 7: 678-689.
114. Lan K, Choudhuri T, Murakami M, et al: Intracellular activated Notch1 is critical for proliferation of Kaposi's sarcoma-associated herpesvirus-associated B-lymphoma cell lines in vitro. J Virol 2006; 80: 6411-6419.
115. Lan K, Murakami M, Choudhuri T, et al: Intracellular-activated Notch1 can reactivate Kaposi's sarcoma-associated herpesvirus from latency. Virology 2006; 351: 393-403.
116. Bhatt S, Ashlock BM, Toomey NL, et al: Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma. J Clin Invest 2013; 123: 26162628.
117. Ramos JC, Sparano JA, Chadburn A, et al: Impact of Myc in HIV-associated nonHodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). Blood 2020; 136: 1284-1297.
118. Tandon N, Ramakrishnan V, Kumar SK: Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. Clin Pharmacol 2016; 8: 35-44. 67
119. Brosh R, Rotter V: When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9: 701-713.
120. Freed-Pastor WA, Prives C: Mutant p53: one name, many proteins. Genes Dev 2012; 26: 1268-1286.
121. Muller PA, Vousden KH: p53 mutations in cancer. Nat Cell Biol 2013; 15: 2-8.
122. Carbone A, Gloghini A, Vaccher E, et al: Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. Br J Haematol 1996; 94: 533-543.
123. Katano H, Sato Y, Sata T: Expression of p53 and human herpesvirus-8 (HHV-8)encoded latency-associated nuclear antigen with inhibition of apoptosis in HHV-8associated malignancies. Cancer 2001; 92: 3076-3084.
124. Boulanger E, Marchio A, Hong SS, et al: Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma. Haematologica 2009; 94: 1170-1174.
125. Amelio I, Mancini M, Petrova V, et al: p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proc Natl Acad Sci U S A 2018; 115: E10869-E10878.
126. Oren M, Rotter V: Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010; 2: a001107. 68
127. Oda E, Ohki R, Murasawa H, et al: Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-1058.
128. Nakano K, Vousden KH: PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683-694.
129. Yu J, Zhang L, Hwang PM, et al: PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7: 673-682.
130. Shibue T, Takeda K, Oda E, et al: Integral role of Noxa in p53-mediated apoptotis response. Genes Dev 2003; 17: 2233-2238.
131. Kenney SC: Reactivation and lytic replication of EBV. eds Arvin A, Campadelli-Fiume G, Mocarski E, et al, In Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Cambridge, 2007.
132. Feng WH, Hong G, Delecluse HJ, et al: Lytic induction therapy for Epstein-Barr viruspositive B-cell lymphomas. J Virol 2004; 78: 1893-1902.
133. Kedes DH, Ganem D: Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997; 99: 2082-2086.
134. Medveczky MM, Horvath E, Lund T, et al: In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 1997; 11: 1327-1332.
論文の公開元へ
